Certain vascular interventions involves the insertion of a procedural sheath through a puncture in an artery. An internal lumen of the procedural sheath provides a passageway for the insertion of an interventional device into the artery and to an area of treatment. In a typical procedure, the procedural sheath is inserted into the artery and an intervention is performed using the interventional device, which is inserted into the artery via the procedural sheath. At the end of the procedure, the procedural sheath is removed from the artery and exchanged with a vessel closure device delivery sheath, which provides a passageway for delivery of a vessel closure device to the opening in the artery.
It is important to achieve hemostasis during the exchange of the procedural sheath with the vessel closure device delivery sheath in order to avoid a loss of blood. Unfortunately, the exchange procedure provides an opportunity for loss of blood and also for damage to the blood vessel as the sheaths are exchanged.
In certain clinical procedures, for example procedures requiring access to the carotid arteries, the consequences of failure to achieve complete hemostasis or causing vessel injury during such an exchange procedure can be extreme. For such transcarotid procedures, if full hemostasis is not achieved, the resultant hematoma may lead to loss of airway passage and/or critical loss of blood to the brain, both of which lead to severe patient compromise and possibly death. Alternately, a vessel injury or dissection may require adjunct repair and lead to prolonged procedure time and risk of complication.
In view of the foregoing, there is a need for vessel access and closure systems for more efficiently delivering a vessel closure device onto a blood vessel. Disclosed is a vessel access and closure assist system for accessing a vessel to perform a vascular intervention, and then facilitating the delivery of a vessel closure device onto a blood vessel for closing an opening in the wall of the blood vessel. The vessel access and closure assist system disclosed herein includes a procedural introducer sheath that directly couples to a vessel closure device delivery sheath such that the procedural introducer sheath does not have to be exchanged with the vessel closure device delivery sheath, as described in detail below.
In one aspect, a blood vessel access and closure assist system, comprising: a procedural introducer sheath sized to be inserted into an artery, the procedural introducer sheath having an internal lumen for delivery of an interventional device into a blood vessel when the introducer sheath is inserted into an artery; a vessel closure device delivery sheath, the vessel closure device delivery sheath having an internal lumen for use with a vessel closure device applier, the internal lumen adapted to deliver a vessel closure device onto a blood vessel; and wherein the vessel closure device delivery sheath and the procedural sheath fixedly couple to one another to form a single assembly that can be inserted into an artery and wherein a distal end of the procedural sheath extends beyond a distal tip of the closure device delivery sheath when the two sheaths are coupled to one another.
In another aspect, there is disclosed A method of treating an artery, comprising: forming a sheath assembly by coupling a procedural introducer sheath to a vessel closure device delivery sheath, wherein the vessel closure device delivery sheath has an internal lumen for delivery of a vessel closure device onto a blood vessel, and wherein the procedural introducer sheath has an internal lumen for delivery of an interventional device into a blood vessel; inserting the sheath assembly into an artery such that the sheath assembly provides a passageway into the artery; inserting an intervention device into the artery via the passageway formed by the sheath assembly; removing the intervention device from the artery; uncoupling the procedural introducer sheath from the vessel closure device delivery sheath so that the procedural introducer sheath is removed from the artery while the vessel closure device delivery sheath remains in the artery; and using the vessel closure device delivery sheath to deliver a vessel closure device to the artery
Other features and advantages should be apparent from the following description of various embodiments, which illustrate, by way of example, the principles of the disclosure.
Disclosed is a vessel access and closure assist system for accessing a vessel to perform a vascular intervention, and then facilitating the delivery of a vessel closure device onto a blood vessel for closing the opening in the wall of the blood vessel. The system is configured for use with a procedural sheath that may be as long as 50 cm. It may be used to deliver a vessel closure device to a vessel access site, such as an incision, puncture, penetration or other passage through the blood vessel.
Because most vessel closure device systems are suitable for introducer sheaths 11 cm or shorter, or require special introducer sheaths, such systems need for a separate sheath to deliver the vessel closure device. The vessel access and closure assist system disclosed herein includes a procedural introducer sheath that directly couples to a vessel closure device delivery sheath such that the procedural introducer sheath does not have to be exchanged with the vessel closure device delivery sheath, as described in detail below. In an embodiment, the system is packaged as a kit that includes a procedural introducer sheath, a sheath dilator, an introducer guide wire, and a vessel closure device delivery sheath. In an embodiment, the kit also includes a vessel closure device applier. In an embodiment, the vessel closure device delivery system is configured for use in a transcarotid procedure performed at least partially on a blood vessel located in the neck of a patient, such as the carotid arteries including the common carotid artery.
As shown in
The procedural sheath 10 is sized and shaped to be inserted into a blood vessel via an access site. In this regard, the procedural sheath 10 has an internal lumen that provides a passageway for inserting an interventional device into the blood vessel. As mentioned, the procedural sheath 10 may be adapted to be introduced through an incision or puncture in a wall of a common carotid artery, either an open surgical incision or a percutaneous puncture established, for example, using the Modified Seldinger technique or a micropuncture technique. The working length of the procedural sheath 10 can be in the range from 11 to 50 cm, usually being from 15 cm to 25 cm. The inner diameter may be in the range from 5 Fr (1 Fr=0.33 mm), to 7 Fr, usually being 6 Fr. The working length is the portion of the procedural sheath that is sized and shaped to be inserted into the artery and wherein at least a portion of the working length is actually inserted into the artery during a procedure.
For certain interventions, it may be desirable for the procedural sheath to have a more flexible distal section. In an embodiment, the working length of the procedural sheath 10 is of a length configured to access the proximal internal carotid artery when inserted from an access location in the common carotid artery (CCA), for example 10-15 cm. In another embodiment the device is has a working length configured to access the distal cervical internal carotid artery (ICA) when inserted from the CCA, for example 15-25 cm. In yet another embodiment, the procedural sheath is of a working length configured to access the petrous, cavernous, or terminal portion of the ICA when inserted from the CCA, for example 20-35 cm. In this embodiment, the distal-most portion (which may have a length of about 3 to about 6 cm) of the procedural sheath may be configured to be more flexible to accommodate the curvature in the petreous portion of the ICA. This additional flexibility may be achieved by using a lower durometer outer jacket material in this section. Alternately, the wall thickness of the jacket material may be reduced, and/or the density of the reinforcement layer may be varied to increase the flexibility. For example the pitch of the coil or braid may be stretched out, or the cut pattern in the tubing may be varied to be more flexible. The distal most portion of the procedural sheath may also be tapered or stepped down to a smaller diameter. In an embodiment, the procedural sheath may include multiple sections of flexibility, with increasing flexibility towards the distal end. U.S. patent application Ser. No. 14/569,365 filed Dec. 12, 2014 and U.S. Pat. No. 8,157,760 describe related systems and are both incorporated herein by reference in their entirety.
The procedural sheath 10 may also include a connection to a flow line or shunt which may be connected to a device for passive or active reverse flow. In an embodiment, the flow line has an internal lumen that communicates with an internal lumen of the procedural sheath 10 for shunting blood from the procedural sheath. In an embodiment, the flow line is a side arm or Y-arm that is attached to and extends from the procedural sheath 10 at a location between the distal and proximal ends of the procedural sheath 10.
The vessel closure device delivery sheath 40 comprises an elongated body 43 and a proximal hub 45 which includes a hemostasis valve 47 and an end cap 46 on the proximal region of the elongated body 43. The proximal hub forms a coupling mechanism that couples to the coupling mechanism of the procedural sheath 10. The vessel closure device delivery sheath 40 has an internal lumen such that it can co-axially fit over the procedural sheath 10 and be shorter than the procedural sheath but still suitable for use in percutaneous procedures, for example in a range between 8 to 11 cm. As noted above, most vessel closure device systems are suitable for introducer sheaths 11 cm or shorter. In an embodiment, the vessel closure device delivery sheath 40 has a working length of 8 to 11 cm and the procedural sheath has a minimum working length of 1 cm greater than the length of the vessel closure device delivery sheath 40, with a range of lengths as described above.
For a system 1 to be configurable for vessel closure devices which can be deployed through standard introducer sheaths, for example, the Mynx Vascular Closure Device (Access Closure), the vessel closure devices can be deployed through a vessel closure device delivery sheath 40 with a standard sheath hemostasis valve 47. In some instances, a vessel closure devices require custom delivery sheaths, for instance, the StarClose (Abbott Vascular) and Angioseal (St. Jude Medical) require delivery sheaths with features that couple with the closure device delivery system. Typically, the custom delivery sheaths are packaged with the closure delivery device and delivery system. At the end of the procedure, the procedural sheath is required to be exchanged for the custom delivery sheath to enable closure with the vessel closure system. For a system 1 to be configurable to these devices, the vessel closure device delivery sheath 40 requires corresponding features to enable deployment of these devices.
The internal lumen of the vessel closure device delivery sheath 40 is sized to receive the procedural sheath 10 such that the procedural sheath 10 can be coupled to the vessel closure device delivery sheath 40 by being positioned co-axially inside the vessel closure device delivery sheath 40. In this regard, the procedural sheath 10 is longer than the closure device delivery sheath 40 such that procedural sheath 10 extends out of the distal end of the vessel closure device delivery sheath 40 when the two are coupled as shown in
In an embodiment, system 1 includes features which couple the vessel closure device delivery sheath 40 and the procedural sheath 10 mechanically together, such that when assembled together the sheaths may be inserted as one, single device into the artery at the start of the procedure such that vessel closure device delivery sheath 40 and the procedural sheath 10 are fixed relative to one another. In one example, the procedure sheath has a rotatable collar 15 on the end of its proximal hub with internal elements such as protrusions or threads that can rotationally engage and lock into grooves on the end cap 46 of the vessel closure device delivery sheath.
To assemble the two devices, the procedure sheath 10 is inserted into the vessel closure device delivery sheath 40 until the rotating collar 15 reaches and engages the end cap 46 of the vessel closure device delivery sheath. The collar 15 can be aligned with the end cap 46 so that the internal elements of the collar can slide into the grooves of the end cap, and then rotate so that the two sheaths are now locked and fixed relative to one another. To un-couple the sheaths, the rotating collar 15 is rotated in the opposite direction to disengage the protrusions or threads on the end cap 46. Alternately, the protrusions are on the vessel closure device delivery sheath end cap 46 and the grooves or threads are on the rotating collar. In another example, the end of the procedure sheath hub 15 has a feature which can snap into the end cap 46 of the vessel closure device delivery sheath 40 when the procedure sheath 10 is inserted into the vessel closure device delivery sheath 40. In this example, the two sheaths are pushed together to mechanically engage one another and pulled apart to disengage from one another.
In another embodiment, the vessel closure device delivery sheath 40 may be positioned anywhere that is suitable for the procedure 10 such that the distal tip of the procedure sheath 10 extends beyond the distal tip of the vessel closure device delivery sheath 40, up to the point where the closure sheath hub 45 abuts the procedure sheath hub 15 and can be manipulated and/or used as an unit or system.
The sheath dilator 20 has an internal lumen sized to co-axially receive an introducer guidewire 30. In an embodiment, the guide wire 30 is an 0.038″ outer diameter guidewire, and the dilator 20 internal lumen diameter and taper shaped are optimized to provide a smooth transition from the dilator 20 to the guide wire 30. In another embodiment, the guide wire 30 is an 0.035″ diameter guidewire, with sheath dilator 20 inner lumen diameter and taper configured accordingly. In another embodiment the guide wire 30 is an 0.018″, an 0.016″, or an 0.014″ OD guide wire, with sheath dilator 20 inner lumen diameter and taper configured accordingly. The guide wire 30 has an atraumatic tip 35 on the distal end. In an embodiment, the guide wire tip 35 has a J-shape. In another embodiment, the guide wire tip 35 is an angled tip. In another embodiment the guide wire has a floppy tip. In an embodiment, the guide wire core is constructed from spring stainless steel. In another embodiment, the guide wire core is constructed from nitinol. In another embodiment, the guide wire core is a combination of stainless steel and nitinol.
As shown in
In an embodiment, the applier 105 is configured to deliver the vessel closure clip 350 to the artery. The clip is deployed from applier 105, transitioning from a cylindrical configuration (as stored) to a flat configuration in the vessel wall (post deployment). In this embodiment, the applier includes a tubular housing 122 which contains the vessel closure clip 350 in the cylindrical configuration and is movably coupled to the shaft 115 to deliver the vessel closure clip 350 to the surface of the vessel. That is, the tubular housing 122 moves along the shaft 115. In this embodiment, the tubular housing 122 is larger in diameter than the shaft 115 such that the tubular housing 122 does not fit through the lumen of the vessel closure device delivery sheath 40. Thus, in this embodiment, the elongated body 43 of the vessel closure device delivery sheath 40 is modifiable to be able to accept the applier 105 as the tubular housing 122 is advanced distally to the distal end of the shaft 115 to deliver the vessel closure device.
In an embodiment, the tubular housing 122 splits or tears apart the body 43 of the vessel closure device delivery sheath 40 as the housing 122 with the closure device 350 is advanced to the distal tip of the shaft 115 and the shaft 115 is in the vessel closure device delivery sheath 40. In an embodiment, the applier 105 includes a sharp blade 120 on the distal end of tubular housing 122 to assist in initiation of the split when the proximal hub 45 of the vessel closure device delivery sheath 40 is coupled to the handle 110 of the applier 105. In another embodiment, the elongated body 43 of the vessel closure device delivery sheath 40 radially expandable such that it can stretch to accommodate insertion of the housing 122 into the vessel closure device delivery sheath 40 as the housing 122 is pushed forward to the distal end of the shaft 115. The materials and construction for this sheath can be but is not limited to splittable polymer such as PTFE or polyethylene, or PET, PE or custom extrusion that has been pre-scored with a blade in order to produce a thinner wall section to facilitate the splitting.
Another exemplary vessel closure device is a plug-type closure device and associated closure device applier. This type of device deposits a plug material such as a collagen plug or polymer material against the outside of the vessel access site and typically expands in situ to create hemostasis at the site. Some devices additionally provide temporary, semi-permanent or permanent anchoring to ensure sufficient compression of the plug against the access site to maintain hemostasis. In an embodiment, the applier 105 is configured to deliver a vessel closure device, such as the type of device described in U.S. Pat. No. 5,676,689. In this example, the vessel closure device delivery sheath 40 is configured to be compatible with this plug device applier. For example, features on the device applier will mate with features on the proximal hub 47 of vessel closure device delivery sheath 40 to ensure that the applier is in the correct orientation with respect to the sheath, The vessel closure device delivery sheath 40 may also include features such as blood inlet holes to ensure that the sheath is in the correct position with respect to the vessel to accurately deposit the plug.
An exemplary method of using the vessel access and closure assist system is now described, as shown in
The procedural sheath 10 is then coupled to the vessel closure device delivery sheath 40 by inserting the procedural sheath 10 into the vessel closure device delivery sheath 40 such that the two are co-axially aligned. Alternately, the vessel closure device delivery sheath 40 is inserted into the procedural sheath 10 in another embodiment. The rotating collar 15 on the procedural sheath engages the end cap 46 on the vessel closure device delivery sheath hub 45 and is rotated to lock the two sheaths together such that they are immobilized relative to one another. When coupled, the two sheaths form a coupled sheath assembly wherein a distal end of the procedural sheath 10 extends out of and/or distally past a distal end of the vessel closure device delivery sheath 40, as shown in
The side arm 18 and stopcock 19 may be used to flush the internal lumen of the procedural sheath 10 as well as inject contrast as desired during the procedure. An interventional device (which may also referred to as a procedural device), such as a balloon catheter, stent delivery catheter, aspiration catheter, thrombectomy catheter, or other working catheter, can then be introduced into the artery via the internal lumens of the coupled sheaths. The devices may be used in conjunction with intermediate or distal access catheters, microcatheters, guide wires, and the like. In this regard, the internal lumen of the procedural sheath 10 provides a passageway for insertion of interventional devices. In an example, the catheter can be used to treat the plaque such as to deploy a stent into a carotid or cerebral artery. As mentioned, a stent delivery catheter and method is just an example of an intervention that can be used in conjunction with the vessel access and closure assist system. Other interventions are possible such as, for example, intracranial balloon angioplasty, intracranial thrombectomy, treatment of intracerebral aneurysms, arteriovenous malformations, or other intracerebral procedures.
At the conclusion of the intervention, the interventional device or devices are then removed from the coupled sheath assembly. The procedural sheath 10 and vessel closure device delivery sheath 40 are then uncoupled either by rotating a connector attached to sheath 10 at hub 15 or by detaching a snap interface at hub 15 from the procedural sheath 10 and pulling sheath 10 out of the vessel closure device delivery sheath 40. The vessel closure device delivery sheath 40 then remains in the artery as shown in
With the vessel closure device delivery sheath 40 positioned in the artery, the shaft 115 (
While this specification contains many specifics, these should not be construed as limitations on the scope of an invention that is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results.
Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
This application is a continuation of U.S. application Ser. No. 14/710,400 entitled “VESSEL ACCESS AND CLOSURE ASSIST SYSTEM AND METHOD” filed May 12, 2015 and Issuing on Jan. 22, 2019 as U.S. Pat. No. 10,182,801 and claims priority to: (1) U.S. Provisional Application Ser. No. 61/994,623 entitled “VESSEL ACCESS AND CLOSURE ASSIST SYSTEM AND METHOD” filed on May 16, 2014; and (2) U.S. Provisional Application Ser. No. 62/074,964 entitled “VESSEL ACCESS AND CLOSURE ASSIST SYSTEM AND METHOD” filed on Nov. 4, 2014, the contents of which are herein incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4301803 | Handa et al. | Nov 1981 | A |
4493707 | Ishihara | Jan 1985 | A |
5007921 | Brown | Apr 1991 | A |
5026390 | Brown | Jun 1991 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5306250 | March et al. | Apr 1994 | A |
5403328 | Shallman | Apr 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5443454 | Tanabe et al. | Aug 1995 | A |
5476469 | Hathaway et al. | Dec 1995 | A |
5520702 | Sauer et al. | May 1996 | A |
5527322 | Klein et al. | Jun 1996 | A |
5549633 | Evans et al. | Aug 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5643289 | Sauer et al. | Jul 1997 | A |
5643292 | Hart | Jul 1997 | A |
5649959 | Hannam et al. | Jul 1997 | A |
5669917 | Sauer et al. | Sep 1997 | A |
5674231 | Green et al. | Oct 1997 | A |
5720757 | Hathaway et al. | Feb 1998 | A |
5746755 | Wood et al. | May 1998 | A |
5766183 | Sauer | Jun 1998 | A |
5769830 | Parker | Jun 1998 | A |
5779719 | Klein et al. | Jul 1998 | A |
5782800 | Yoon | Jul 1998 | A |
5792152 | Klein et al. | Aug 1998 | A |
5797929 | Andreas et al. | Aug 1998 | A |
5810846 | Virnich et al. | Sep 1998 | A |
5810850 | Hathaway et al. | Sep 1998 | A |
5833650 | Imran | Nov 1998 | A |
5860990 | Nobles et al. | Jan 1999 | A |
5860991 | Klein et al. | Jan 1999 | A |
5902311 | Andreas et al. | May 1999 | A |
5916193 | Stevens et al. | Jun 1999 | A |
5921994 | Andreas et al. | Jul 1999 | A |
6004341 | Zhu et al. | Dec 1999 | A |
6024747 | Kontos | Feb 2000 | A |
6030395 | Nash et al. | Feb 2000 | A |
6036699 | Andreas et al. | Mar 2000 | A |
6042601 | Smith | Mar 2000 | A |
6077279 | Kontos | Jun 2000 | A |
6110185 | Barra et al. | Aug 2000 | A |
6117144 | Nobles et al. | Sep 2000 | A |
6117145 | Wood et al. | Sep 2000 | A |
6132440 | Hathaway et al. | Oct 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6146370 | Barbut | Nov 2000 | A |
6146373 | Cragg et al. | Nov 2000 | A |
6190396 | Whitin et al. | Feb 2001 | B1 |
6197042 | Ginn et al. | Mar 2001 | B1 |
6206868 | Parodi | Mar 2001 | B1 |
6206893 | Klein et al. | Mar 2001 | B1 |
6245079 | Nobles et al. | Jun 2001 | B1 |
6277140 | Ginn et al. | Aug 2001 | B2 |
6295989 | Connors, III | Oct 2001 | B1 |
6302898 | Edwards et al. | Oct 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6348059 | Hathaway et al. | Feb 2002 | B1 |
6355050 | Andreas et al. | Mar 2002 | B1 |
6358258 | Arcia et al. | Mar 2002 | B1 |
6364900 | Heuser | Apr 2002 | B1 |
6368334 | Sauer | Apr 2002 | B1 |
6379325 | Benett et al. | Apr 2002 | B1 |
6391048 | Ginn et al. | May 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6423032 | Parodi | Jul 2002 | B2 |
6423086 | Barbut et al. | Jul 2002 | B1 |
6428549 | Kontos | Aug 2002 | B1 |
6435189 | Lewis et al. | Aug 2002 | B1 |
6436109 | Kontos | Aug 2002 | B1 |
6454741 | Muni et al. | Sep 2002 | B1 |
6461364 | Ginn et al. | Oct 2002 | B1 |
6482172 | Thramann | Nov 2002 | B1 |
6517553 | Klein et al. | Feb 2003 | B2 |
6533800 | Barbut | Mar 2003 | B1 |
6540712 | Parodi et al. | Apr 2003 | B1 |
6551331 | Nobles et al. | Apr 2003 | B2 |
6558399 | Isbell et al. | May 2003 | B1 |
6562049 | Norlander et al. | May 2003 | B1 |
6562052 | Nobles et al. | May 2003 | B2 |
6569182 | Balceta et al. | May 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6589214 | McGuckin, Jr. et al. | Jul 2003 | B2 |
6595953 | Coppi et al. | Jul 2003 | B1 |
6596003 | Realyvasquez, Jr. et al. | Jul 2003 | B1 |
6623471 | Barbut | Sep 2003 | B1 |
6623510 | Carley et al. | Sep 2003 | B2 |
6626886 | Barbut | Sep 2003 | B1 |
6626918 | Ginn et al. | Sep 2003 | B1 |
6632238 | Ginn et al. | Oct 2003 | B2 |
6641592 | Sauer et al. | Nov 2003 | B1 |
6645222 | Parodi et al. | Nov 2003 | B1 |
6652480 | Imran et al. | Nov 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6695867 | Ginn et al. | Feb 2004 | B2 |
6719717 | Johnson et al. | Apr 2004 | B1 |
6719777 | Ginn et al. | Apr 2004 | B2 |
6730102 | Burdulis, Jr. et al. | May 2004 | B1 |
6746457 | Dana et al. | Jun 2004 | B2 |
6749621 | Pantages et al. | Jun 2004 | B2 |
6790197 | Kosinski et al. | Sep 2004 | B2 |
6837881 | Barbut | Jan 2005 | B1 |
6840949 | Barbut | Jan 2005 | B2 |
6847234 | Choi | Jan 2005 | B2 |
6855136 | Dorros et al. | Feb 2005 | B2 |
6884235 | McGuckin, Jr. et al. | Apr 2005 | B2 |
6902540 | Dorros et al. | Jun 2005 | B2 |
6905490 | Parodi | Jun 2005 | B2 |
6908474 | Hogendijk et al. | Jun 2005 | B2 |
6932824 | Roop et al. | Aug 2005 | B1 |
6936060 | Hogendijk et al. | Aug 2005 | B2 |
6942674 | Belef et al. | Sep 2005 | B2 |
6958059 | Zadno-Azizi | Oct 2005 | B2 |
6964668 | Modesitt et al. | Nov 2005 | B2 |
7001398 | Carley et al. | Feb 2006 | B2 |
7001400 | Modesitt et al. | Feb 2006 | B1 |
7004924 | Brugger et al. | Feb 2006 | B1 |
7004931 | Hogendijk | Feb 2006 | B2 |
7004952 | Nobles et al. | Feb 2006 | B2 |
7029480 | Klein et al. | Apr 2006 | B2 |
7029487 | Greene, Jr. et al. | Apr 2006 | B2 |
7033344 | Imran | Apr 2006 | B2 |
7048747 | Arcia et al. | May 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7063714 | Dorros et al. | Jun 2006 | B2 |
7083594 | Coppi | Aug 2006 | B2 |
7090686 | Nobles et al. | Aug 2006 | B2 |
7094246 | Anderson et al. | Aug 2006 | B2 |
7144411 | Ginn et al. | Dec 2006 | B2 |
7208008 | Clarke | Apr 2007 | B2 |
7232452 | Adams et al. | Jun 2007 | B2 |
7367982 | Nash et al. | May 2008 | B2 |
7374561 | Barbut | May 2008 | B2 |
7390328 | Modesitt | Jun 2008 | B2 |
7396359 | Derowe et al. | Jul 2008 | B1 |
7422579 | Wahr et al. | Sep 2008 | B2 |
7458980 | Barbut | Dec 2008 | B2 |
8157760 | Criado et al. | Apr 2012 | B2 |
8545432 | Renati et al. | Oct 2013 | B2 |
10039906 | Kume et al. | Aug 2018 | B2 |
10085864 | Chou et al. | Oct 2018 | B2 |
10159479 | Hentges et al. | Dec 2018 | B2 |
10182801 | Garrison | Jan 2019 | B2 |
20010003158 | Kensey et al. | Jun 2001 | A1 |
20010044638 | Levinson et al. | Nov 2001 | A1 |
20010049486 | Evans et al. | Dec 2001 | A1 |
20020077600 | Sirimanne | Jun 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20030004543 | Gleeson et al. | Jan 2003 | A1 |
20030036755 | Ginn | Feb 2003 | A1 |
20030093093 | Modesitt et al. | May 2003 | A1 |
20050131453 | Parodi | Jun 2005 | A1 |
20050154344 | Chang | Jul 2005 | A1 |
20050154349 | Renz et al. | Jul 2005 | A1 |
20050251162 | Rothe et al. | Nov 2005 | A1 |
20050267520 | Modesitt | Dec 2005 | A1 |
20060064124 | Zhu et al. | Mar 2006 | A1 |
20060106338 | Chang | May 2006 | A1 |
20060111741 | Nardella | May 2006 | A1 |
20060167476 | Burdulis et al. | Jul 2006 | A1 |
20060200191 | Zadno-Azizi | Sep 2006 | A1 |
20060282088 | Ryan | Dec 2006 | A1 |
20060287673 | Brett et al. | Dec 2006 | A1 |
20070198049 | Barbut | Aug 2007 | A1 |
20070270888 | Barrientos | Nov 2007 | A1 |
20080045979 | Ma | Feb 2008 | A1 |
20080058839 | Nobles et al. | Mar 2008 | A1 |
20080097479 | Boehlke et al. | Apr 2008 | A1 |
20080140010 | Kennedy et al. | Jun 2008 | A1 |
20080188890 | Weitzner et al. | Aug 2008 | A1 |
20080221614 | Mas | Sep 2008 | A1 |
20080287967 | Andreas et al. | Nov 2008 | A1 |
20080312686 | Ellingwood | Dec 2008 | A1 |
20090018455 | Chang | Jan 2009 | A1 |
20090024072 | Criado et al. | Jan 2009 | A1 |
20090143789 | Houser | Jun 2009 | A1 |
20090198172 | Garrison et al. | Aug 2009 | A1 |
20090254166 | Chou et al. | Oct 2009 | A1 |
20100042118 | Garrison et al. | Feb 2010 | A1 |
20100191169 | Chang | Jul 2010 | A1 |
20100191170 | Chang | Jul 2010 | A1 |
20100204684 | Garrison et al. | Aug 2010 | A1 |
20100217276 | Garrison et al. | Aug 2010 | A1 |
20100228269 | Garrison et al. | Sep 2010 | A1 |
20100280431 | Criado et al. | Nov 2010 | A1 |
20110004147 | Renati et al. | Jan 2011 | A1 |
20110034986 | Chou et al. | Feb 2011 | A1 |
20110166496 | Criado et al. | Jul 2011 | A1 |
20110166497 | Criado et al. | Jul 2011 | A1 |
20130317481 | Ellingwood et al. | Nov 2013 | A1 |
20140058414 | Garrison et al. | Feb 2014 | A1 |
20140135661 | Garrison et al. | May 2014 | A1 |
20140296769 | Hyde et al. | Oct 2014 | A1 |
20140296868 | Garrison et al. | Oct 2014 | A1 |
20150025616 | Chang | Jan 2015 | A1 |
20150080942 | Garrison et al. | Mar 2015 | A1 |
20150141760 | Chou et al. | May 2015 | A1 |
20150150562 | Chang | Jun 2015 | A1 |
20150174368 | Garrison et al. | Jun 2015 | A1 |
20150327843 | Garrison | Nov 2015 | A1 |
20160128688 | Garrison et al. | May 2016 | A1 |
20160158044 | Chou et al. | Jun 2016 | A1 |
20160158502 | Kume et al. | Jun 2016 | A1 |
20160166804 | Garrison et al. | Jun 2016 | A1 |
20160242764 | Garrison et al. | Aug 2016 | A1 |
20160271315 | Chang | Sep 2016 | A1 |
20160271316 | Criado et al. | Sep 2016 | A1 |
20160279379 | Chang | Sep 2016 | A1 |
20160296690 | Ku Me et al. | Oct 2016 | A1 |
20160317288 | Rogers et al. | Nov 2016 | A1 |
20170043141 | Kume et al. | Feb 2017 | A1 |
20170136212 | Garrison et al. | May 2017 | A1 |
20170209260 | Garrison et al. | Jul 2017 | A1 |
20170296798 | Kume et al. | Oct 2017 | A1 |
20170312491 | Ryan et al. | Nov 2017 | A1 |
20170354523 | Chou et al. | Dec 2017 | A1 |
20170354803 | Kume et al. | Dec 2017 | A1 |
20170361072 | Chou et al. | Dec 2017 | A1 |
20170368296 | Chang | Dec 2017 | A1 |
20180008294 | Garrison et al. | Jan 2018 | A1 |
20180154063 | Criado et al. | Jun 2018 | A1 |
20180185614 | Garrison et al. | Jul 2018 | A1 |
20180235789 | Wallace et al. | Aug 2018 | A1 |
20180289884 | Criado et al. | Oct 2018 | A1 |
20190105439 | Criado et al. | Apr 2019 | A1 |
20190150916 | Hentges et al. | May 2019 | A1 |
20190175885 | Kume et al. | Jun 2019 | A1 |
20190231962 | Criado et al. | Aug 2019 | A1 |
20190254680 | Chang | Aug 2019 | A1 |
20190262530 | Criado et al. | Aug 2019 | A1 |
20190269538 | Chou et al. | Sep 2019 | A1 |
20190366070 | Kume et al. | Dec 2019 | A1 |
20190388654 | Chou et al. | Dec 2019 | A1 |
20200009406 | Garrison et al. | Jan 2020 | A1 |
20200015826 | Chang | Jan 2020 | A1 |
20200016321 | Criado et al. | Jan 2020 | A1 |
20200038576 | Garrison et al. | Feb 2020 | A1 |
20200054871 | Ryan et al. | Feb 2020 | A1 |
20200108221 | Chang | Apr 2020 | A1 |
20200113587 | Garrison et al. | Apr 2020 | A1 |
20200170637 | Garrison et al. | Jun 2020 | A1 |
20200171277 | Garrison et al. | Jun 2020 | A1 |
20200282127 | Garrison et al. | Sep 2020 | A1 |
20200297912 | Criado et al. | Sep 2020 | A1 |
Number | Date | Country |
---|---|---|
0 669 103 | Aug 1995 | EP |
S59-161808 | Oct 1984 | JP |
H07-265412 | Oct 1995 | JP |
H08-07161 | Mar 1996 | JP |
H08-033666 | Mar 1996 | JP |
10-052490 | Feb 1998 | JP |
2001-523492 | Nov 2001 | JP |
2002-522149 | Jul 2002 | JP |
2002-543914 | Dec 2002 | JP |
2003-521299 | Jul 2003 | JP |
2007-301326 | Nov 2007 | JP |
WO-9925419 | May 1999 | WO |
WO-0009028 | Feb 2000 | WO |
WO-0056223 | Sep 2000 | WO |
WO-0069350 | Nov 2000 | WO |
WO-0076390 | Dec 2000 | WO |
WO-0154588 | Aug 2001 | WO |
WO-02096295 | Dec 2002 | WO |
WO-03071955 | Sep 2003 | WO |
WO-2004060169 | Jul 2004 | WO |
WO-2005051206 | Jun 2005 | WO |
WO-2006128017 | Nov 2006 | WO |
WO-2009012473 | Jan 2009 | WO |
WO-2009099764 | Aug 2009 | WO |
WO-2009100210 | Aug 2009 | WO |
WO-2010019719 | Feb 2010 | WO |
WO-2012021406 | Feb 2012 | WO |
Entry |
---|
Bergeron et al. (2008) MEET Presentation, Cannes, French Riviera “Why I do not use routine femoral access for CAS.” 12 pages. |
Bettmann, M. et al, “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012. |
Bhatt, D. L., R. E. Raymond, et al. (2002). “Successful “pre-closure” of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Multicenter Interventional Closer Registry).” Am J Cardiol 89(6): 777-9. |
Blanc, R., C. Mounayer, et al. (2002). “Hemostatic closure device after carotid puncture for stent and coil placement in an intracranial aneurysm: technical note.” AJNR Am J Neuroradiol 23(6): 978-81. |
Blanc, R., M. Piotin, et al. (2006). “Direct cervical arterial access for intracranial endovascular treatment.” Neuroradiology 48(12): 925-9. |
Chang, D.W., et al, “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002.). |
Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261. |
Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483. |
Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8. |
Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7. |
Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331. |
Hoffer et al. “Percutaneous Arterial Closure Devices” J. Vasc. Interv. Radiol. 14:865-885 (2003). |
Howell, M., K. Doughtery, et al. (2002). “Percutaneous repair of abdominal aortic aneurysms using the AneuRx stent graft and the percutaneous vascular surgery device.” Catheter Cardiovasc Interv 55(3): 281-7. |
Massiere, B., A. von Ristow, et al. (2009). “Closure of Carotid Artery Puncture Site With a Percutaneous Device.” Ann Vasc Surg. 23(2): 256 e5-7. |
Ribo et al. (2006). “Transcranial doppler monitoring of transcervical carotid stenting with flow reversal protection: a novel carotid revascularization technique” 37:2846-2849 (originally published online Sep. 28, 2006). |
Ruiz et al., “Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure” Catheterization and Cardiovascular interventions 71:921-926 (2008). |
Stejskal, et al., “Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy”, Acta Neurochir, 2007, 149:681-689. |
Bergeron, P. (2015, First Published Feb. 1, 2015 Research Article Find in PubMed). “Direct Percutaneous Carotid Access for Carotid Angioplasty and Stenting.” Journal of Endovascular Therapy, 22(1), 135-138. https://doi.org/10.1177/1526602814564362. |
Bergeron, P., et al. (1999, First Published May 1, 1999 Research Article). “Percutaneous Stenting of the Internal Carotid Artery: The European CAST I Study.” Journal of Endovascular Therapy. 6(2), 155-159. https://doi.org/10.1177/152660289900600207. |
U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769. |
U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764. |
U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, US 2016-0317288. |
U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260. |
U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, US 2017-0296798. |
U.S. Appl. No. 15/901,502, filed Feb. 21, 2018, US 2018-0235789. |
U.S. Appl. No. 16/056,208, filed Aug. 6, 2018, US 2019-0175885. |
U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, US 2019-0269538. |
U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512. |
U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, US 2019-0150916. |
U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654. |
U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, US 2020-0038576. |
U.S. Appl. No. 16/299,524, filed Mar. 14, 2019, US 2020-0009406. |
U.S. Appl. No. 16/353,492, filed Mar. 12, 2019, US 2019-0366070. |
U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962. |
U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, US 2020-0170637. |
U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871. |
U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, US 2020-0171277. |
U.S. Appl. No. 16/547,042, filed Aug. 21, 2019, US 2020-0113587. |
U.S. Appl. No. 16/880,594, filed May 21, 2020, US 2020-0282127. |
U.S. Appl. No. 16/894,474, filed Jun. 5, 2020, US 2020-0297912. |
U.S. Appl. No. 14/078,149, filed Nov. 12, 2013, US 2014-0135661. |
U.S. Appl. No. 14/935,252, filed Nov. 6, 2015, US 2016-0128688. |
U.S. Appl. No. 15/489,055, filed Apr. 17, 2017, US 2017-0312491. |
U.S. Appl. No. 15/613,921, filed Jun. 5, 2017, US 2017-0368296. |
U.S. Appl. No. 15/628,190, filed Jun. 20, 2017, US 2018-0008294. |
U.S. Appl. No. 15/728,747, filed Oct. 10, 2017, US 2018-0154063. |
U.S. Appl. No. 15/728,915, filed Oct. 10, 2017, US 2018-0185614. |
U.S. Appl. No. 16/008,703, filed Jun. 14, 2018, US 2018-0289884. |
U.S. Appl. No. 16/210,533, filed Dec. 5, 2018, US 2019-0105439. |
PCT/US18/18943, Feb. 21, 2018, WO 2018/156574. |
PCT/US18/40264, Jun. 29, 2018, WO 2019/010077. |
Number | Date | Country | |
---|---|---|---|
20190350568 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62074964 | Nov 2014 | US | |
61994623 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14710400 | May 2015 | US |
Child | 16250825 | US |